Skip to main content
TipRanks
Go Ultimate75% OFF

Castle Biosciences (CSTL) Net Revenue by Segment

474 Followers

Net Revenue by Segment

Castle Biosciences reported net revenue by segment of $102.89M in Q3 2026, down 0.6% from Q2 2026 and up 23.9% year over year. The highest value was $103.55M in Q2 2026.

Shows how much money each part of the business brings in — for Castle Biosciences that typically means different diagnostic tests, services, and regions. Reveals whether growth is coming from a single flagship test or from broader product adoption, highlights concentration risk if one segment dominates, and points to where reimbursement, pricing, or commercial efforts are succeeding or need more investment.

$0.00$20.00M$40.00M$60.00M$80.00M$100.00MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

Revenue mix is shifting: Non‑dermatologic businesses have moved from a niche contributor into a co‑equal (now leading) growth engine, powered by rapid TissueCypher expansion and other non‑derm tests, while the once‑dominant dermatologic cohort rolled over after mid‑2024 peaks—partly seasonal and partly pressured by DecisionDx‑SCC reimbursement timing and capacity/cost investments. Management’s raised guidance and volume momentum support further top‑line upside, but sustainable margin improvement hinges on mix normalization, reimbursement clarity, and successful commercialization of Advanced ADTx.

CSTL Net Revenue by Segment

PeriodDermatologicNon-DermatologicTotal
Q3 2026Sep 30, 2026$47.88M$55.01M$102.89M
Q2 2026Jun 30, 2026$48.70M$54.84M$103.55M
Q1 2026Mar 31, 2026$41.10M$42.57M$83.68M
Q4 2025Dec 31, 2025$48.59M$38.42M$87.01M
Q3 2025Sep 30, 2025$48.52M$34.52M$83.04M
Q2 2025Jun 30, 2025$56.30M$29.89M$86.19M
Q1 2025Mar 31, 2025$62.96M$25.03M$87.99M
Q4 2024Dec 31, 2024$63.77M$22.54M$86.31M
Q3 2024Sep 30, 2024$65.06M$20.72M$85.78M
Q2 2024Jun 30, 2024$68.83M$18.17M$87.00M
Q1 2024Mar 31, 2024$59.33M$13.64M$72.97M
Q4 2023Dec 31, 2023$53.28M$12.84M$66.12M
Q3 2023Sep 30, 2023$51.15M$10.34M$61.49M
Q2 2023Jun 30, 2023$43.03M$7.11M$50.14M
Q1 2023Mar 31, 2023$35.91M$6.13M$42.04M
Q4 2022Dec 31, 2022$34.65M$3.69M$38.34M
Q3 2022Sep 30, 2022$33.92M$3.09M$37.01M
Q2 2022Jun 30, 2022$31.90M$2.94M$34.84M
Q1 2022Mar 31, 2022$24.34M$2.51M$26.85M
Q4 2021Dec 31, 2021$22.87M$2.17M$25.04M
Q3 2021Sep 30, 2021$21.59M$1.88M$23.48M
Q2 2021Jun 30, 2021$20.38M$2.38M$22.76M
Q1 2021Mar 31, 2021$20.91M$1.90M$22.81M

Related KPIs